home / open_comments

documents

Federal regulatory documents currently open for public comment.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

184 rows where agency_id = "FDA" sorted by comment_end_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: subtype, posted_year, posted_month, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)

document_type 3

  • Other 110
  • Notice 70
  • Proposed Rule 4

agency_id 1

  • FDA · 184 ✖
id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date ▲ last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2026-N-0131-0001 FDA FDA-2026-N-0131 FDA Rare Disease Innovation Hub Future Programming; Request for Comments Notice Request for Comments 2026-01-30 2026 1 2026-01-30 2027-01-01 2026-03-22 09:00:09 2026-01903 1 0 09000064b91893ee
FDA-2016-D-1280-0005 FDA FDA-2016-D-1280 Electronic Submission of Postmarketing Individual Case Safety Reports to the Food and Drug Administration Adverse Event Monitoring System Using International Council of Harmonisation E2B(R3) Data Standards; Regional Data Elements and Implementation Schedule Notice Announcement 2026-04-06 2026 4 2026-04-06 2026-10-02 2026-04-07 09:00:25 2026-06660 1 0 09000064b9253dbc
FDA-2025-E-2426-0006 FDA FDA-2025-E-2426 Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA Notice Determinations 2026-02-13 2026 2 2026-02-13 2026-08-13 2026-02-13 20:03:13 2026-02901 1 0 09000064b91aa6fb
FDA-2025-E-0152-0006 FDA FDA-2025-E-0152 Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY Notice Determinations 2026-02-06 2026 2 2026-02-06 2026-08-06 2026-02-06 20:05:43 2026-02388 1 0 09000064b919467e
FDA-2025-E-0153-0006 FDA FDA-2025-E-0153 Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY Notice Determinations 2026-02-06 2026 2 2026-02-06 2026-08-06 2026-02-06 20:06:34 2026-02388 1 0 09000064b919467f
FDA-2024-E-3539-0006 FDA FDA-2024-E-3539 Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZ Notice Determinations 2026-02-06 2026 2 2026-02-06 2026-08-06 2026-02-14 13:19:52 2026-02387 1 0 09000064b9195b4d
FDA-2025-E-0154-0006 FDA FDA-2025-E-0154 Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY Notice Determinations 2026-02-06 2026 2 2026-02-06 2026-08-06 2026-02-06 20:07:01 2026-02388 1 0 09000064b9195c17
FDA-2026-N-3273-0001 FDA FDA-2026-N-3273 Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments Notice Request for Comments 2026-04-15 2026 4 2026-04-15 2026-07-24 2026-04-15 17:05:22 2026-07248 1 0 09000064b9282224
FDA-2026-P-0749-0001 FDA FDA-2026-P-0749 Citizen Petition from Apotex Inc. Other Citizen Petition 2026-01-26 2026 1 2026-01-26 2026-07-23 2026-01-27 01:08:18   1 0 09000064b9182c73
FDA-2026-D-1255-0002 FDA FDA-2026-D-1255 Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry Other Guidance 2026-04-15 2026 4 2026-04-15 2026-07-15 2026-04-16 09:00:16   1 0 09000064b9282a2a
FDA-2023-N-0119-0020 FDA FDA-2023-N-0119 Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments Notice Request for Comments 2026-02-27 2026 2 2026-02-27 2026-07-11 2026-04-14 09:00:18 2026-03961 1 0 09000064b91e326c
FDA-2026-N-2366-0001 FDA FDA-2026-N-2366 Commissioner’s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments Notice Request for Comments 2026-03-23 2026 3 2026-03-23 2026-06-30 2026-04-12 09:00:14 2026-05573 1 0 09000064b922c21a
FDA-2026-N-2742-0001 FDA FDA-2026-N-2742 Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification Notice 60 Day Proposed Information Collection 2026-04-10 2026 4 2026-04-10 2026-06-10 2026-04-10 18:01:37 2026-06936 1 0 09000064b926825a
FDA-2026-N-2743-0001 FDA FDA-2026-N-2743 Agency Information Collection Activities; Proposed Collection; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503 Notice 60 Day Proposed Information Collection 2026-04-10 2026 4 2026-04-10 2026-06-10 2026-04-10 18:22:24 2026-06935 1 0 09000064b926821b
FDA-2026-N-2915-0001 FDA FDA-2026-N-2915 Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Approval of Medical Devices Notice 60 Day Proposed Information Collection 2026-04-10 2026 4 2026-04-10 2026-06-10 2026-04-10 17:47:50 2026-06906 1 0 09000064b9268328
FDA-2026-N-2431-0001 FDA FDA-2026-N-2431 Agency Information Collection Activities; Proposed Collection; Comment Request; Administrative Practices and Procedures; Formal Hearings Notice 60 Day Proposed Information Collection 2026-04-07 2026 4 2026-04-07 2026-06-09 2026-04-14 19:40:33 2026-06719 1 0 09000064b9255485
FDA-2025-E-0863-0006 FDA FDA-2025-E-0863 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:37:03 2026-06478 1 0 09000064b924cccb
FDA-2025-E-0845-0006 FDA FDA-2025-E-0845 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:34:01 2026-06478 1 0 09000064b924dac3
FDA-2025-E-0866-0006 FDA FDA-2025-E-0866 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:42:13 2026-06478 1 0 09000064b924ccce
FDA-2025-E-0372-0005 FDA FDA-2025-E-0372 Determination of Regulatory Review Period for Purposes of Patent Extension; ZIIHERA Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:52:42 2026-06476 1 0 09000064b924da88
FDA-2025-E-3074-0006 FDA FDA-2025-E-3074 Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:57:30 2026-06480 1 0 09000064b924c470
FDA-2025-E-0871-0006 FDA FDA-2025-E-0871 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:49:10 2026-06478 1 0 09000064b924c46e
FDA-2025-E-3073-0006 FDA FDA-2025-E-3073 Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:55:54 2026-06480 1 0 09000064b924da86
FDA-2025-E-3626-0006 FDA FDA-2025-E-3626 Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:59:57 2026-06479 1 0 09000064b924d98d
FDA-2025-E-0870-0006 FDA FDA-2025-E-0870 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:48:07 2026-06478 1 0 09000064b924c46d
FDA-2026-N-2740-0001 FDA FDA-2026-N-2740 Agency Information Collection Activities; Proposed Collection; Comment Request; Customer/Partner Customer Service Satisfaction Surveys Notice 60 Day Proposed Information Collection 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:29:44 2026-06482 1 0 09000064b924dac4
FDA-2025-E-0868-0006 FDA FDA-2025-E-0868 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:44:23 2026-06478 1 0 09000064b924c0e1
FDA-2025-E-0865-0006 FDA FDA-2025-E-0865 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:39:45 2026-06478 1 0 09000064b924cccd
FDA-2025-E-1672-0007 FDA FDA-2025-E-1672 Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 18:06:28 2026-06477 1 0 09000064b924d940
FDA-2014-E-2328-0006 FDA FDA-2014-E-2328 Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 18:09:13 2026-06483 1 0 09000064b924d4f5
FDA-2025-E-0864-0006 FDA FDA-2025-E-0864 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:38:27 2026-06478 1 0 09000064b924cccc
FDA-2025-E-0872-0006 FDA FDA-2025-E-0872 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:50:02 2026-06478 1 0 09000064b924c46f
FDA-2025-E-0867-0006 FDA FDA-2025-E-0867 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:43:31 2026-06478 1 0 09000064b924c0e0
FDA-2025-E-0158-0006 FDA FDA-2025-E-0158 Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 18:04:00 2026-06481 1 0 09000064b924d942
FDA-2025-E-0869-0006 FDA FDA-2025-E-0869 Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY Notice Determinations 2026-04-03 2026 4 2026-04-03 2026-06-03 2026-04-03 17:45:32 2026-06478 1 0 09000064b924ba07
FDA-2026-C-3071-0001 FDA FDA-2026-C-3071 Filing of Color Additive Petition: International Association of Color Manufacturers; Request to Amend the Color Additive Regulations to Remove the Solvents Methylene Chloride, Trichloroethylene, and Ethylene Dichloride Proposed Rule Petition 2026-04-01 2026 4 2026-04-01 2026-06-02 2026-04-01 17:16:12 2026-06295 1 0 09000064b9249960
FDA-2026-N-0809-0001 FDA FDA-2026-N-0809 Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments Notice Request for Comments 2026-03-03 2026 3 2026-03-03 2026-06-02 2026-04-13 09:00:28 2026-04196 1 0 09000064b91ed501
FDA-2026-N-2476-0001 FDA FDA-2026-N-2476 Advancing the Use of Digital Health Technologies in Clinical Investigations for Drugs and Biological Products; Request for Information and Comments Notice Request for Comments 2026-03-31 2026 3 2026-03-31 2026-06-02 2026-04-10 09:00:28 2026-06184 1 0 09000064b92439d6
FDA-2026-N-2590-0001 FDA FDA-2026-N-2590 Microbiology Devices; Reclassification of Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests Proposed Rule Request for Comment 2026-03-30 2026 3 2026-03-30 2026-05-30 2026-04-13 09:00:30 2026-06064 1 0 09000064b92437b6
FDA-2024-E-5140-0006 FDA FDA-2024-E-5140 Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM Notice Determinations 2025-11-24 2025 11 2025-11-24 2026-05-27 2026-01-24 13:16:48 2025-20667 1 0 09000064b908e3f0
FDA-2024-E-5139-0006 FDA FDA-2024-E-5139 Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM Notice Determinations 2025-11-24 2025 11 2025-11-24 2026-05-27 2026-01-24 13:16:48 2025-20667 1 0 09000064b908e3ef
FDA-2024-E-5141-0006 FDA FDA-2024-E-5141 Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM Notice Determinations 2025-11-24 2025 11 2025-11-24 2026-05-27 2026-01-24 13:16:50 2025-20667 1 0 09000064b9092f99
FDA-2024-E-5681-0006 FDA FDA-2024-E-5681 Determination of Regulatory Review Period for Purposes of Patent Extension; ALTIUS DIRECT ELECTRICAL NERVE STIMULATION SYSTEM Notice Determinations 2025-11-24 2025 11 2025-11-24 2026-05-27 2025-11-24 19:32:14 2025-20668 1 0 09000064b9093521
FDA-2026-N-2365-0001 FDA FDA-2026-N-2365 Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Associated With Animal Drug and Animal Generic Drug User Fees Notice 60 Day Proposed Information Collection 2026-03-23 2026 3 2026-03-23 2026-05-23 2026-03-23 17:37:47 2026-05620 1 0 09000064b922c25e
FDA-2026-N-2364-0001 FDA FDA-2026-N-2364 Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Advisory Committees Notice 60 Day Proposed Information Collection 2026-03-23 2026 3 2026-03-23 2026-05-23 2026-03-25 09:00:29 2026-05623 1 0 09000064b922c187
FDA-2025-D-2837-0002 FDA FDA-2025-D-2837 Questions and Answers About Requirements for Additional Traceability Records for Certain Foods: Guidance for Industry - Draft Guidance Other Guidance 2026-02-20 2026 2 2026-02-20 2026-05-22 2026-02-20 20:47:16   1 0 09000064b91c9d9a
FDA-2026-N-1304-0001 FDA FDA-2026-N-1304 Agenda for the U.S. Food and Drug Administration (FDA) Virtual Public Meeting Food Allergen Thresholds and Their Potential Applications 2-18-2026 Other Agenda 2026-02-18 2026 2 2026-02-18 2026-05-20 2026-04-10 09:00:23   1 0 09000064b91b5eeb
FDA-2025-N-5996-0001 FDA FDA-2025-N-5996 Medical Devices; Radiology Devices; Classification of Blood Irradiators Proposed Rule Notice of Proposed Rulemaking (NPRM) 2026-03-18 2026 3 2026-03-18 2026-05-19 2026-03-29 09:00:14 2026-05320 1 0 09000064b92216a5
FDA-2025-N-5995-0001 FDA FDA-2025-N-5995 Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis Proposed Rule Notice of Proposed Rulemaking (NPRM) 2026-03-18 2026 3 2026-03-18 2026-05-19 2026-03-21 09:00:16 2026-05322 1 0 09000064b92215cb
FDA-2026-N-1849-0001 FDA FDA-2026-N-1849 Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Notifications Submission Notice 60 Day Proposed Information Collection 2026-03-19 2026 3 2026-03-19 2026-05-19 2026-03-19 17:24:48 2026-05329 1 0 09000064b9224334
FDA-2026-N-2279-0001 FDA FDA-2026-N-2279 Preparation for International Cooperation on Cosmetics Regulation Twentieth Annual Meeting (ICCR–20); Request for Comments Notice Request for Comments 2026-03-18 2026 3 2026-03-18 2026-05-19 2026-04-03 09:00:22 2026-05280 1 0 09000064b922165c
FDA-2025-D-6131-0002 FDA FDA-2025-D-6131 General Considerations for the Use of New Approach Methodologies in Drug Development; Guidance for Industry - Draft Guidance Other Guidance 2026-03-19 2026 3 2026-03-19 2026-05-19 2026-04-15 09:00:24   1 0 09000064b9223609
FDA-2026-N-1736-0001 FDA FDA-2026-N-1736 Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements Notice 60 Day Proposed Information Collection 2026-03-13 2026 3 2026-03-13 2026-05-13 2026-03-13 17:05:05 2026-04938 1 0 09000064b92145ad
FDA-2026-D-1817-0002 FDA FDA-2026-D-1817 Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications—Considerations Related to Youth Risk - Draft Guidance for Industry Other Guidance 2026-03-11 2026 3 2026-03-11 2026-05-12 2026-04-14 09:00:19   1 0 09000064b920c96d
FDA-2011-D-0611-0094 FDA FDA-2011-D-0611 New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) Guidance for Industry - Draft Guidance Other Guidance 2026-03-10 2026 3 2026-03-10 2026-05-12 2026-03-14 09:00:14   1 0 09000064b92071bb
FDA-2025-N-4731-0052 FDA FDA-2025-N-4731 Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments Notice Request for Comments 2026-04-15 2026 4 2026-04-15 2026-05-09 2026-04-15 17:08:45 2026-07335 1 0 09000064b9282192
FDA-2025-D-1504-0002 FDA FDA-2025-D-1504 Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry Other Guidance 2026-03-09 2026 3 2026-03-09 2026-05-09 2026-04-10 09:00:26   1 0 09000064b9200f6d
FDA-2025-E-0493-0006 FDA FDA-2025-E-0493 Determination of Regulatory Review Period for Purposes of Patent Extension; ENSACOVE Notice Determinations 2026-03-06 2026 3 2026-03-06 2026-05-06 2026-03-06 19:06:30 2026-04491 1 0 09000064b91f8458
FDA-2024-D-4388-0002 FDA FDA-2024-D-4388 New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers Guidance for Industry - Draft Guidance Other Guidance 2026-03-04 2026 3 2026-03-04 2026-05-05 2026-03-09 09:00:19   1 0 09000064b91ef6ec
FDA-2026-N-2741-0001 FDA FDA-2026-N-2741 Consideration of Acceptable Market Name Change for Certain Rockfish (Sebastes spp.); Request for Information Notice Requests for Information (RFI) 2026-04-01 2026 4 2026-04-01 2026-05-02 2026-04-14 19:40:35 2026-06294 1 0 09000064b924995a
FDA-2026-N-1867-0001 FDA FDA-2026-N-1867 Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—New Drug Application 220359, for Camizestrant Tablets; Supplemental New Drug Application (sNDA) 218197/S–004, for Truqap (Capivasertib) Tablets Notice Request for Comments 2026-03-09 2026 3 2026-03-09 2026-04-30 2026-04-16 09:00:12 2026-04497 1 0 09000064b9200842
FDA-2007-D-0369-2444 FDA FDA-2007-D-0369 PSG_020151 - Draft Guidance on Venlafaxine Hydrochloride Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:22:37   1 0 09000064b91df4e6
FDA-2007-D-0369-2442 FDA FDA-2007-D-0369 PSG_020144 - Draft Guidance on Nitroglycerin Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:21:57   1 0 09000064b91df4d8
FDA-2007-D-0369-2432 FDA FDA-2007-D-0369 PSG_018084 - Draft Guidance on Tolmetin Sodium Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:18:51   1 0 09000064b91df465
FDA-2007-D-0369-2457 FDA FDA-2007-D-0369 PSG_021336 - Draft Guidance on Selegiline Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:26:39   1 0 09000064b91e011b
FDA-2007-D-0369-2440 FDA FDA-2007-D-0369 PSG_019982 - Draft Guidance on Bisoprolol Fumarate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:21:21   1 0 09000064b91df4d4
FDA-2007-D-0369-2447 FDA FDA-2007-D-0369 PSG_020375 - Draft Guidance on Estradiol Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:23:38   1 0 09000064b91df4f2
FDA-2007-D-0369-2438 FDA FDA-2007-D-0369 PSG_019813 - Draft Guidance on Fentanyl Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:20:47   1 0 09000064b91df4d0
FDA-2007-D-0369-2459 FDA FDA-2007-D-0369 PSG_021427 - Draft Guidance on Duloxetine Hydrochloride Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:27:37   1 0 09000064b91e011f
FDA-2007-D-0369-2461 FDA FDA-2007-D-0369 PSG_021514 - Draft Guidance on Methylphenidate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:29:28   1 0 09000064b91e0123
FDA-2007-D-0369-2520 FDA FDA-2007-D-0369 PSG_218466 - Draft Guidance on Alpelisib Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:50:12   1 0 09000064b91e01d3
FDA-2007-D-0369-2511 FDA FDA-2007-D-0369 PSG_216352 - Draft Guidance on Paliperidone Palmitate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:47:03   1 0 09000064b91e01b4
FDA-2007-D-0369-2512 FDA FDA-2007-D-0369 PSG_216665 - Draft Guidance on Diazoxide Choline Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:47:20   1 0 09000064b91e01b6
FDA-2007-D-0369-2508 FDA FDA-2007-D-0369 PSG_215431 - Draft Guidance on Meloxicam; Rizatriptan Benzoate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:46:07   1 0 09000064b91e01ad
FDA-2007-D-0369-2475 FDA FDA-2007-D-0369 PSG_202211 - Draft Guidance on Oxybutynin Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:35:11   1 0 09000064b91e0140
FDA-2007-D-0369-2466 FDA FDA-2007-D-0369 PSG_022029 - Draft Guidance on Menthol; Methyl Salicylate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:31:54   1 0 09000064b91e012d
FDA-2007-D-0369-2467 FDA FDA-2007-D-0369 PSG_022083 - Draft Guidance on Rivastigmine Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:32:28   1 0 09000064b91e012f
FDA-2007-D-0369-2464 FDA FDA-2007-D-0369 PSG_021829 - Draft Guidance on Rotigotine Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:30:54   1 0 09000064b91e0129
FDA-2007-D-0369-2497 FDA FDA-2007-D-0369 PSG_213224 - Draft Guidance on Octreotide acetate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:42:17   1 0 09000064b91e018a
FDA-2007-D-0369-2490 FDA FDA-2007-D-0369 PSG_211843 - Draft Guidance on Tiopronin Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:39:55   1 0 09000064b91e0172
FDA-2007-D-0369-2481 FDA FDA-2007-D-0369 PSG_207620 - Draft Guidance on Sacubitril; Valsartan Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:37:17   1 0 09000064b91e0156
FDA-2007-D-0369-2489 FDA FDA-2007-D-0369 PSG_211733 - Draft Guidance on Acetaminophen; Ibuprofen Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:39:39   1 0 09000064b91e0170
FDA-2007-D-0369-2479 FDA FDA-2007-D-0369 PSG_206089 - Draft Guidance on Testosterone Undecanoate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:36:31   1 0 09000064b91e0152
FDA-2007-D-0369-2469 FDA FDA-2007-D-0369 PSG_022264 - Draft Guidance on Paliperidone Palmitate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:33:09   1 0 09000064b91e0133
FDA-2007-D-0369-2473 FDA FDA-2007-D-0369 PSG_085635 - Draft Guidance on Testosterone Cypionate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:34:27   1 0 09000064b91e013c
FDA-2007-D-0369-2488 FDA FDA-2007-D-0369 PSG_210868 - Draft Guidance on Lorlatinib Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:39:21   1 0 09000064b91e016e
FDA-2007-D-0369-2486 FDA FDA-2007-D-0369 PSG_209310 - Draft Guidance on Mometasone Furoate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:38:46   1 0 09000064b91e016a
FDA-2007-D-0369-2506 FDA FDA-2007-D-0369 PSG_215401 - Draft Guidance on Dextroamphetamine Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:45:23   1 0 09000064b91e01a9
FDA-2007-D-0369-2522 FDA FDA-2007-D-0369 PSG_218585 - Draft Guidance on Aceclidine Hydrochloride Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:51:02   1 0 09000064b91e01d7
FDA-2007-D-0369-2509 FDA FDA-2007-D-0369 PSG_215602 - Draft Guidance on Baclofen Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:46:21   1 0 09000064b91e01af
FDA-2007-D-0369-2516 FDA FDA-2007-D-0369 PSG_217225 - Draft Guidance on Avacincaptad Pegol Sodium Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:48:56   1 0 09000064b91e01cb
FDA-2007-D-0369-2507 FDA FDA-2007-D-0369 PSG_215429 - Draft Guidance on Venlafaxine Besylate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:45:49   1 0 09000064b91e01ab
FDA-2007-D-0369-2443 FDA FDA-2007-D-0369 PSG_020145 - Draft Guidance on Nitroglycerin Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:22:16   1 0 09000064b91df4da
FDA-2007-D-0369-2460 FDA FDA-2007-D-0369 PSG_021447 - Draft Guidance on Tizanidine Hydrochloride Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:27:59   1 0 09000064b91e0121
FDA-2007-D-0369-2446 FDA FDA-2007-D-0369 PSG_020357 - Draft Guidance on Metformin Hydrochloride Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:23:14   1 0 09000064b91df4f0
FDA-2007-D-0369-2448 FDA FDA-2007-D-0369 PSG_020489 - Draft Guidance on Testosterone Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:23:57   1 0 09000064b91df4f4
FDA-2007-D-0369-2454 FDA FDA-2007-D-0369 PSG_021234 - Draft Guidance on Diclofenac Epolamine Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:25:35   1 0 09000064b91e010a
FDA-2007-D-0369-2500 FDA FDA-2007-D-0369 PSG_214410 - Draft Guidance on Baloxavir Marboxil Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:43:31   1 0 09000064b91e0190
FDA-2007-D-0369-2494 FDA FDA-2007-D-0369 PSG_212516 - Draft Guidance on Duloxetine Hydrochloride Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:41:20   1 0 09000064b91e0184
FDA-2007-D-0369-2484 FDA FDA-2007-D-0369 PSG_208143 - Draft Guidance on Barium Sulfate Other Guidance 2026-02-27 2026 2 2026-02-27 2026-04-29 2026-02-27 19:38:13   1 0 09000064b91e015c

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
            id TEXT PRIMARY KEY,
            agency_id TEXT,
            docket_id TEXT,
            title TEXT,
            document_type TEXT,
            subtype TEXT,
            posted_date TEXT,
            posted_year INTEGER,
            posted_month INTEGER,
            comment_start_date TEXT,
            comment_end_date TEXT,
            last_modified TEXT,
            fr_doc_num TEXT,
            open_for_comment INTEGER,
            withdrawn INTEGER,
            object_id TEXT
        );
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date);
CREATE INDEX idx_docs_withdrawn ON documents(withdrawn);
Powered by Datasette · Queries took 1557.106ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API